BrightInsight, a digital health solutions provider based in San Jose, announced a US$13 million funding round on January 20, 2026, led by existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners.

The capital will fund the development of AI-enabled medication adherence solutions and support the expansion of programs like the patient app, developed in collaboration with Sanofi and Regeneron.

Medication non-adherence remains a significant challenge, contributing to an estimated 125,000 preventable deaths annually and up to 25% of hospitalizations in the US, with associated healthcare costs reaching US$100 billion to US$300 billion yearly.

BrightInsight plans to incorporate AI into its platform to generate patient-specific insights, improve predictions of medication churn, and expand its ecosystem to include caregivers and nurse educators.

The company aims to address persistent issues in patient engagement and medication adherence through its digital solutions.

🔗 Source: BrightInsight